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Abstract: One-third of patients with epilepsy continue to have seizures despite current
treatments, indicating the need for better antiseizure medications with novel mechanisms of
action. Ezogabine (retigabine) has recently been approved for adjunctive treatment of partialonset seizures in adult patients with epilepsy. Ezogabine utilizes a novel mechanism of action,
involving activation of specific potassium channels. The most common side effects of ezogabine
are shared by most antiseizure medications and primarily consist of central nervous system
(CNS) symptoms, such as somnolence, dizziness, confusion, and fatigue. In addition, a small
percentage of patients on ezogabine experience a unique adverse effect affecting the bladder,
which results in urinary hesitancy; thus, patients on ezogabine should be monitored carefully for
potential urological symptoms. Overall, ezogabine appears to be well tolerated and represents
a reasonable new option for treating patients with intractable epilepsy.
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Epilepsy is a common disease with a cumulative lifetime risk of at least 3%.1 It is associated with significant morbidity and mortality, as well as decreased quality of life in
a variety of social, educational, and vocational measures.2–4 Specifically, mortality has
been demonstrated to be up to threefold higher in developed countries.5 Further, adults
with seizures are at risk for lower levels of education, higher rates of unemployment,
and psychological and physical ailments.6 A number of new antiseizure medications
have been developed and marketed in the last two decades. Despite these new therapies,
medically intractable epilepsy, defined as persistent seizures after an adequate trial
of two appropriate antiseizure medications, continues to occur in approximately onethird of cases.7,8 This makes the development of antiseizure medications with novel
mechanisms of action an important goal to further broaden the possible success in
intractable epilepsy of various etiologies. However, with novel mechanisms of action
there is a risk of unique side effects.
One of these new antiseizure medications with a novel mechanism of action is
ezogabine (EZG). EZG is an ethyl N-(2-amino-4-{[(4-fluorophenyl)methyl]amino}
phenyl) (Figure 1) and is known by the international nonproprietary name of “retigabine”
in Europe and most of the world. This drug was recently approved by the European
Medicines Agency and the US Food and Drug Administration (FDA) for adjunctive
treatment of partial-onset seizures in adults. It appears to work by a unique mechanism
of action compared with other currently available antiepileptic drugs. A number of
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Figure 1 Chemical structure of ezogabine.

other recent reviews have also highlighted different aspects
of EZG,9–13 but this review focuses especially on the adverse
effects of EZG.

Mechanism of action
First developed through the National Institutes of Health
Antiepileptic Drug Development program after the identification of a structural analog’s (flupirtine) efficacy against
seizures, EZG’s mechanism of action is novel among
currently available antiseizure medications.14 EZG exerts
its effects on the Kv7 family of potassium channels15,16 by
binding to the cytoplasmic aspects of the S5 and S6 parts of
the activation gate of these potassium channels involved in
the M-current.17,18 In doing so, EZG increases rates of channel
opening, maintains potassium channels in the open state for
longer periods of time, and alters the voltage characteristics
of the cell, making channel opening more likely.16
The channels bound by EZG consist of the Kv7 homoand heteromeric subunits KCNQ2–5.15,16,19 EZG’s primary
site of action is the KCNQ2/3 heteromer,15,16 which is
expressed in the nervous system and accounts for its
antiseizure efficacy. There is no enhancement of the potassium currents mediated by the KCNQ1 channel subunit,
which is found primarily in cardiac tissue18 and also in the
gastrointestinal system and brain.20 However, KCNQ4 and
KCNQ5 potassium channels are activated by EZG and may
be found in cochlear hair cells21 or smooth muscle.22 EZG
causes relaxation of smooth muscle in the bladder, which
probably accounts for the adverse effects of EZG on urinary
function.23

Metabolism–drug interactions
EZG is absorbed rapidly after oral administration, with a
peak plasma concentration at 1.5 hours after ingestion.24
EZG is metabolized primarily by acetylation and glucuronidation in the liver and is subsequently eliminated by renal
excretion.25,26 Due to this dual metabolism, it is recommended that individuals with low creatinine clearance
(,50 mL/min), undergoing hemodialysis, or with moderate
to severe hepatic impairment start at a lower starting dose
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(50 mg/d) and titrate to a lower maximum dose (600 mg/d
for renal failure or severe hepatic impairment; 750 mg/d for
moderate hepatic impairment). In patients 66–81 years of
age, it has been noted that EZG clearance was diminished
compared with younger study participants (18–40 years of
age) and the authors attributed this to the normal decrease
in creatinine clearance that occurs with age. No side effects
from this difference were noted.27
As in vitro studies have demonstrated little or no potential
for EZG to inhibit or induce the major cytochrome,28 P450
isoenzymes, minimal drug interactions of clinical significance have been reported. EZG does not interact with oral
contraceptive agents.29 Moreover, it seems to be well tolerated
in individuals taking other antiseizure medications as well,
with minimal direct interactions. While EZG and lamotrigine
had reciprocal effects on renal clearance, both drugs were
tolerated equally well alone and in combination, thus these
interactions were not thought clinically significant.30 No clinically significant interactions have been found between EZG
and propofol, valproate, or imipramine26 and an in vivo study
has demonstrated lack of interaction between phenobarbitone
and EZG.31 In clinical studies, no significant pharmacokinetic
effect has been seen on phenytoin, carbamazepine, valproic
acid or topiramate.32 Overall, EZG has few clinically significant interactions with other pharmaceutical agents.

Efficacy
Three double-blind placebo-controlled multicenter trials have
taken place investigating the efficacy of EZB in adults with
medically intractable partial-onset epilepsy as add-on therapy
in combination with other antiepileptic medications.33–35
A recent paper has reported an integrated analysis of these
three controlled trials.36 After pooling data from the three
studies, 1240 patients were included, with 813 patients
randomized to EZG and 427 to placebo. In all trials, after
an initial 8-week baseline phase, patients were randomized
to placebo or EZB (titrated to 600, 900, or 1200 mg/day,
depending on the trial), followed by an 8–12-week maintenance phase. Two primary efficacy measures were used:
(1) responder rate, defined as the percentage of patients experiencing a $50% reduction in seizure frequency compared
with the baseline phase; and (2) the percent change in partial
seizure frequency. A number of secondary efficacy endpoints
were also assessed, including more specific categorization
of seizure frequency reduction rates and the proportion of
seizure-free days and seizure-free patients.
Analysis of the integrated data found statistically
signif icant effects of EZB on both primary eff icacy
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measures.36 Responder rates ($50% reduction in seizure
frequency) were 35% and 45% for EZG at 600 and
900 mg/day, respectively, compared with 21% for placebo
(P , 0.001) and 50% for EZG at 1200 mg/day, compared
with 24% for placebo (P , 0.001). Average reduction in
seizure frequency was 26%, 37%, and 39% for 600, 900, and
1200 mg/d EZG, respectively, all of which were statistically
significantly greater than placebo (15%). Similar differences
were observed in various secondary endpoints. For example,
the proportion of patients experiencing a 50%–75% or $75%
reduction in seizures showed a dose-dependent increase
with EZG compared with placebo. At all doses, there was a
significant increase in seizure-free days with EZG compared
with placebo, although the effect was modest (81%–84% for
EZG vs 78% for placebo). In addition, while in the individual
trials there had been no statistically significant effect of EZG
on the percentage of seizure-free patients, in the pooled
analysis of EZG at 1200 mg/d, but not at 600 or 900 mg/d,
there was a statistically significant increase in the proportion
of seizure-free patients during the maintenance phase (15%
with 1200 mg/d EZG vs 5% with placebo).
Subgroup analyses did not demonstrate any differences in the magnitude of the effect of EZG based on age
(18–44 years vs .44 years), sex, race (white vs nonwhite),
region (US vs non-US), number of baseline antiseizure
medications, and seizure subtypes (simple partial, complex
partial, secondary generalized). Overall, these randomized
placebo-controlled trials demonstrated that EZG is effective
as add-on therapy for adults with intractable partial-onset
epilepsy. The magnitude of the effects of EZG on seizures
is similar to most other new antiseizure medications used as

adjunctive therapy for intractable epilepsy and only a small
percentage of patients become seizure-free on EZG.

Adverse events
Over the course of the three major placebo-controlled
trials,33–35 EZG was generally quite well tolerated. Based
on the pooled analysis, adverse events that were considered severe were similar in the placebo (10%), EZG
600 mg/d (10%), and EZG 900 mg/d (12%) groups but
were higher in the EZG 1200 mg/d group (20%).36 All other
adverse events were noted by investigators to be mild to
moderate. Three deaths (0.7%) related to sudden death in
epilepsy, injury, and respiratory failure occurred in the 427
patients on placebo, whereas only two deaths (0.2%) in the
cumulative EZG groups due to sudden death in epilepsy and
diabetic ketoacidosis occurred in the 813 patients. Discontinuation of the study due to adverse events occurred in 10%,
15%, 24%, and 28% of patients in the placebo, 600 mg/d,
900 mg/d, and 1200 mg/d groups, respectively.36
Reasons for discontinuation of the study and the overall most common adverse events were generally central
nervous system (CNS) related (Table 1). These adverse
events occurred with increasing frequency as the dose of
EZG was increased. The most common side effects included
dizziness and somnolence and, to a lesser extent, confusion,
fatigue, and asthenia.33–35 Porter et al33 noted speech difficulties in no patients in the placebo arms and five (5%), twelve
(12.6%), and 17 (16%) patients in the 600 mg/d, 900 mg/d,
and 1200 mg/d arms, respectively.
EZG has been noted to decrease gastrointestinal smooth
muscle contractility.37,38 Constipation was not mentioned

Table 1 Adverse effects of ezogabine reported in at least 5% of patients with intractable partial seizures in placebo-controlled add-on
clinical trials

Dizziness
Somnolence
Confusion
Headache
Fatigue
Coordination disturbance
Blurred vision
Memory impairment
Vertigo
Nausea
Attention disturbance
Urinary/renal
Discontinued due to adverse events
Death

Placebo,
n = 427 (%)

Ezogabine 600 mg/d,
n = 281 (%)

Ezogabine 900 mg/d,
n = 273 (%)

Ezogabine 1200 mg/d,
n = 259 (%)

38 (8.9)
51 (11.9)
11 (2.6)
68 (15.9)
25 (5.9)
12 (2.8)
9 (2.1)
11 (2.6)
9 (2.1)
22 (5.2)
4 (,1)
55 (12.9)
39 (9.1)
3

41 (14.6)
43 (15.3)
12 (4.3)
34 (12.1)
45 (16)
14 (5)
5 (1.8)
7 (2.5)
22 (7.8)
18 (6.4)
17 (6)
38 (13.5)
41 (14.6)
1

64 (23.4)
67 (24.5)
21 (7.7)
47 (17.2)
40 (14.7)
14 (5.1)
12 (4.4)
15 (5.5)
21 (7.7)
17 (6.2)
15 (5.5)
35 (12.8)
65 (23.8)
0

84 (32.4)
69 (26.6)
42 (16.2)
39 (15.1)
34 (13.1)
30 (11.6)
27 (10.4)
24 (9.3)
24 (9.3)
22 (8.5)
17 (6.6)
65 (25.1)
73 (28.2)
1

Adapted from Epilepsy Res. Porter et al; Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials. © 2012,
with permission from Elsevier.36
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in two studies33,35 but occurred in three (2%) patients in the
placebo arm and nine (5.9%) patients in the 1200 mg/d group
French et al’s study.34 Alterations in liver enzyme levels
were noted rarely but were transient and did not require
discontinuation from the studies.33–35 No changes in electrocardiography have been reported. Adverse events related to
cardiac abnormalities were similar in the placebo (4%) and
EZG (5%) groups.
While most of the reported side effects of EZG are
similar to many other antiseizure medications in that they
most commonly affect the CNS, EZG has one relatively
unique and specific adverse effect, which is related to urinary function.37 EZG had initially been noted to relax rat
bladders39 as well as decrease bladder tension and contraction
amplitude.40 As a result of this basic science data, urinary
adverse events were recorded during the placebo-controlled
trials. In Brodie et al’s trial,35 three patients were discharged
from these trials for urinary symptoms, although the groups
to which these patients were assigned were not delineated:
one for nephritis and two for urinary hesitation. French et al34
reported nine (5.9%) patients in the 1200 mg/d arm and one
(0.7%) in the placebo arm with urinary hesitation and eight
(5.2%) patients in the 1200 mg/d arm and two (1.3%) in the
placebo arm with dysuria. In the pooled analysis, urinary or
renal symptoms were reported in the EZG 1200 mg/d group
(25%) almost twice as frequently as in the placebo (13%)
group, although similar rates as in the placebo group were
reported with 600 mg/d (14%) and 900 mg/d (13%).35,36 Other
urinary symptoms and signs reported included urinary tract
infections, polyuria, hematuria, proteinuria, and chromaturia.
These adverse events were noted to diminish with time on the
medication and were noted to be mild to moderate. Very few
cases led to discontinuation (1% for both EZG and placebo).
Due to the urinary symptoms, the FDA has required postmarketing analysis and recording of urinary symptoms.
Some data from the open-label extension trial have
now been published in a recent review.37 There continues
to be no evidence of direct renal adverse events, although
one participant did have reversible renal failure related to
obstructive uropathy.37 Of note, four participants have now
been reported with nephrolithiasis in the 1200 mg/d group.37
However, based on the overall incidence of nephrolithiasis in
the USA and EZG’s mechanism of action, it is not felt that
ezogabine is an independent risk factor for nephrolithiasis at
this time. Urinary crystals with an appearance similar to bilirubin have been reported in some participants.37 This could
result in an abnormal urinalysis result but does not appear
to be related to a risk for nephrolithiasis. Overall, it would
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seem prudent to monitor any patients on EZG for urologic
symptoms and be cautious with those with risk factors for
urinary obstruction.
No data are available on the safety of EZG use during
pregnancy. As such, EZG is a pregnancy class C drug. In
addition, there is a lack of established safety data on infants
of breastfeeding mothers on EZG.

Other clinical applications
A variety of additional clinical applications beyond epilepsy have been proposed for EZG. These include in
neuromyotonia,41 neuropathic pain,42,43 mania, and addiction
to psychostimulants.44 Other rodent models have demonstrated a possible anti-dystonic effect.45 An in vitro study has
demonstrated a possible anxiolytic effect of EZG.46 However,
these other applications are still under investigation.

Discussion and conclusion
Epilepsy, despite several new medications that have been
developed in the last few decades, continues to be refractory
to medications in one-third of patients and can be a significant
cause of morbidity and mortality. EZG is a new antiseizure
drug with a novel mechanism of action. It is a potassiumchannel activator primarily active in the CNS, with alternate
sites of action in the urinary bladder, gastrointestinal smooth
muscle, and vascular smooth muscle.47,48
EZG has proven efficacy and is approved both in the USA
and Europe for treatment of adults with intractable partialonset epilepsy. Given its novel mechanism of action, there
is hope that EZG may be more effective for some patients
with intractable epilepsy than other available antiseizure
medications, although, overall, the efficacy data are fairly
comparable to studies of other drugs in intractable patients.
Early data demonstrate minimal interaction with medications
other than lamotrigine and those interactions were deemed
to be clinically insignificant.30
EZG is generally well tolerated and is rarely discontinued
due to adverse events. The number of reported adverse events
is also likely to be influenced by the forced fast titration
schedule deemed necessary by the authors of the placebocontrolled trials. Most of these adverse events were CNS
related, such as somnolence and fatigue.
However, EZG has a novel adverse effect on the urinary
tract – specifically, on the urinary bladder – both in animal
models and in human trials. Urinary or secondary renal
adverse effects are collectively relatively common, occurring
in about 25% of patients in the highest-dose EZG group.36,37
Symptoms from urinary adverse events were usually noted
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to be minor or moderate, sometimes only involving laboratory abnormalities on urinalysis and rarely leading to discontinuation from the trial. However, urinary hesitancy and
retention can be clinically significant problems. Thus, due to
this novel side effect and the lack of a significant quantity of
long-term data as to the severity and prevalence of urinary
adverse events, the FDA has recommended a risk evaluation
and mitigation strategy to further track the use of EZG in
this regard. Overall, no long-term data currently exist as to
the safety of EZG.
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